Table 1 Clinical and laboratory findings of the patients with primary eosinophilia
From: FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia
No | Diagnosis | Sex | Age | Clinical presentation | WBC/eosinophils (×109/L) | Hb (g/dl) | PLT (×109/L) | Previous therapy | Imatinib dosage | Duration of imatinib therapy | Result of imatinib therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | CEL | M | 34 | Maculopapular rash, fatigue, peripheral neuropathy, splenomegaly | 20.4/11.4 | 12.5 | 210 | - | 400 mg (I) 100 mg (M) | 35 mo | CHR, clinical, molecular remission |
2 | CEL | M | 22 | Splenomegaly | 27.0/10.2 | 13.1 | 157 | - | 100 mg (I) 100 mg (M) | 11 mo | CHR, clinical, molecular remission |
3 | Idiopathic HES | M | 23 | Abdominal pain, lymphadeno-pathy, fatigue, cough | 36.1/16.2 | 13 | 310 | Steroids for 6 mo | 400 mg (I) 100 mg (M) | 54 mo | CHR |
4 | Idiopathic HES | M | 38 | Cough, asthma | 21.9/14.0 | 14.8 | 268 | - | 400 mg (I) 400 mg (M) | 13 mo | CHR |
5 | SM-Eo | F | 37 | Malaise, arthralgia, gastritis, splenomagaly | 13.8/5.5 | 12.7 | 673 | IFN-a for 2 y | 400 mg | 12 mo | No response |